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Glioblastoma harbors a dynamic subpopulation of
glioblastoma stem-like cells (GSCs) that can propa-
gate tumors in vivo and is resistant to standard
chemoradiation. Identification of the cell-intrinsic
mechanisms governing this clinically important cell
state may lead to the discovery of therapeutic strate-
gies for this challenging malignancy. Here, we
demonstrate that the mitotic E3 ubiquitin ligase
CDC20-anaphase-promoting complex (CDC20-APC)
drives invasiveness and self-renewal in patient tu-
mor-derived GSCs. Moreover, CDC20 knockdown
inhibited and CDC20 overexpression increased the
ability of human GSCs to generate brain tumors in
an orthotopic xenograft model in vivo. CDC20-APC
control of GSC invasion and self-renewal operates
through pluripotency-related transcription factor
SOX2. Our results identify a CDC20-APC/SOX2
signaling axis that controls key biological properties
of GSCs, with implications for CDC20-APC-targeted
strategies in the treatment of glioblastoma.
INTRODUCTION
Glioblastoma, the most common malignant primary brain tumor
in adults, remains a challenging disease with a poor prognosis
(Wen and Kesari, 2008). Increasing appreciation of the cancer
cell heterogeneity within glioblastomas has focused attentionCeon a subpopulation of cells called tumor-initiating cells or
glioblastoma stem-like cells (GSCs) (Singh et al., 2004). GSCs
contribute to overall tumor growth as well as tumor recurrence
following chemoradiation, and they exhibit elevated invasive po-
tential compared to their non-stem-cell counterparts (Bao et al.,
2006; Chen et al., 2012; Cheng et al., 2011). GSCs also retain the
genetic features of parental tumors, suggesting they are a faithful
model system for human glioblastoma (Lee et al., 2006; Pollard
et al., 2009).
The anaphase-promoting complex (APC) E3 ubiquitin ligase
functions with co-activator CDC20 to drive mitosis (Peters,
2006). CDC20-APC has been viewed as a potential strategic
target in several human cancers (Wang et al., 2015). CDC20
mRNA is elevated in glioblastoma compared to low-grade gli-
omas, and CDC20 immunoreactivity in gliomas correlates with
pathological grade, but little is known about the biological roles
of CDC20-APC in glioblastoma (Bie et al., 2011; Marucci et al.,
2008). Recent studies have revealed unexpected non-mitotic
roles for CDC20-APC in the developing mammalian brain, indi-
cating CDC20-APC executes functions beyond the cell cycle
(Kim et al., 2009; Puram et al., 2011; Yang et al., 2009). These
observations have important ramifications not only for brain
development but also raise the possibility that CDC20-APC
may function in the aberrant developmental state of GSCs.
Here we report CDC20-APC is required for GSC invasiveness
and self-renewal in a manner distinct from its role in cell-cycle
control. We identify pluripotency-related transcription factor
SOX2 as a CDC20-interacting protein and show CDC20-APC
operates through SOX2 to regulate human GSC invasion and
self-renewal. Finally, we demonstrate that CDC20-APC is essen-
tial for GSC tumorigenicity in orthotopic xenografts and thatll Reports 11, 1809–1821, June 23, 2015 ª2015 The Authors 1809
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Figure 1. CDC20-APC Controls GSC Invasion and Self-Renewal
(A) GSC lines were subjected to immunofluorescence with indicated antibodies and Hoechst nuclear stain. Scale bar, 50 mm.
(B) B18 GSCs were injected into the right putamen of NOD-SCID mice and animals were sacrificed after 3 months. Sectioned brains were subjected to
immunohistochemistry with the indicated antibodies. Nuclei were stained with DAPI. White box highlights tumor. Scale bar, 100 mm.
(C) Lysates from GSC lines and normal human astrocytes (NHA) were processed for immunoblotting using the indicated antibodies.
(D) B18 GSCs were transduced with CDC20 RNAi (CDC20i.1 and CDC20i.2) or control scrambled (Scr) lentivirus; 7 days later, cell lysates were subjected to
immunoblotting using the indicated antibodies. Similar results were seen with control viruses SHC002 and LacZ RNAi (data not shown).
(E) GSCs treated as in (D) were subjected to the in vitro Matrigel transwell assay 6 days after infection. Data represent mean + SEM. CDC20 knockdown inhibited
GSC invasiveness compared to control (ANOVA, p = 0.001 and p < 0.0001 for CDC20i.1 and CDC20i.2, respectively; n = 4).
(F) GSCs transduced with the indicated lentiviruses were subjected to the in vitro Matrigel transwell assay as in (E). Data represent mean + SEM. CDC20 RNAi
decreased GSC invasiveness compared to control (ANOVA, p < 0.003; n = 3). Expression of CDC20-Res rescued the CDC20 RNAi-triggered invasion phenotype
(ANOVA, p = 0.003). Vec, control vector virus.
(legend continued on next page)
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CDC20 expression has prognostic value in a subset of glio-
blastoma patients. These results highlight a critical role for
CDC20-APC in the maintenance of human GSC function, and
they suggest that targeting this pathway in glioblastoma may
disrupt the GSC state.
RESULTS
We have generated low-passage patient-derived GSC lines (Ta-
ble S1), which express neural stem cell markers (Figures 1A and
S1A–S1C), exhibit self-renewal in vitro (Figure S1D), and form
infiltrative brain tumors in immunocompromised mice (Figures
1B and S1E; Pollard et al., 2009). We examined CDC20 expres-
sion by immunoblotting in multiple GSC lines and found
increased protein levels in GSCs compared to primary human
astrocytes (Figure 1C). To test the role of CDC20 in GSCs, we
used RNAi lentiviruses to target human CDC20 (CDC20i.1 and
CDC20i.2), which resulted in efficient CDC20 knockdown (Fig-
ure 1D). We focused first on invasiveness, a defining clinical
feature of gliomas. GSCs transduced with CDC20 RNAi were
subjected to an in vitro Matrigel invasion assay, which quantita-
tively assessed invasion through an extracellular matrix-coated
filter (Figure 1E).CDC20 knockdown by two distinct RNAi viruses
inhibited GSC invasiveness by 55% and 95%, respectively
(Figure 1E).
To demonstrate the specificity of the CDC20 RNAi phenotype,
we performed a rescue experiment using rat Cdc20 (herein
CDC20-Res), which shares 94.8% amino acid (aa) identity with
human CDC20 but harbors four base mismatches within the
sequence targeted by CDC20i.2, rendering it insensitive to
CDC20i.2 (Figure S2A). The inhibition of GSC invasiveness by
CDC20 knockdown was reversed by co-expression of CDC20-
Res, demonstrating the specificity of the CDC20 RNAi pheno-
type (Figure 1F). To test the generalizability of CDC20’s role in
GSC invasion, we subjected two additional patient tumor-
derived GSC lines to CDC20 knockdown and similarly found
that CDC20 RNAi decreased invasiveness (Figures S2B and
S2C). CDC20 overexpression also increased the invasive capac-
ity of three human GSC lines (Figures 1G, 1H, S2D, and S2E).(G) B18 GSCs transduced with GFP-CDC20-Res-expressing lentivirus were sub
(H) GSCs transduced with GFP-CDC20-Res-expressing or control vector lentiviru
CDC20 overexpression increased GSC invasion compared to control (unpaired t
(I) B18 GSCs were transduced with ANAPC2 RNAi (ANAPC2i) or control scramb
using the indicated antibodies. Similar results were seen using control virus SHC
(J) GSCs treated as in (I) were subjected to the in vitro Matrigel transwell assay 6
invasiveness compared to control (unpaired t test, p = 0.001; n = 4).
(K) B18GSCswere subjected to the in vitro Matrigel transwell assay in the presenc
invasion in a dose-dependent manner (ANOVA, p < 0.003; n = 3).
(L) GSCs infected with CDC20i.2 or control (Scr) virus were subjected to the extr
counted and analyzed. Data represent mean + SEM. CDC20 RNAi decreased
p = 0.0002; n = 3).
(M) B18 GSCs infected with CDC20-expressing or control virus were treated a
percentage of self-renewing GSCs compared to control (unpaired t test, p = 0.0
(N) A1GSCs treated as in (M) were subjected to the extreme limiting dilution assay
of self-renewing GSCs compared to control infection (unpaired t test, p = 0.009;
(O) GSCswere subjected to the extreme limiting dilution assaywith 10 mMProTAM
decreased the percentage of self-renewing GSCs compared to vehicle (unpaired
See also Table S1 and Figures S1–S3.
CeThus, through both loss-of-function and gain-of-function ap-
proaches, CDC20 is necessary and sufficient for GSC invasion
in vitro.
Next, we determined whether CDC20 operates with the
APC to control GSC invasiveness. We knocked down APC 2
(ANAPC2), the essential catalytic subunit of the APC, and found
that ANAPC2 RNAi inhibited GSC invasiveness in three human
GSC lines (Figures 1I, 1J, S2B, and S2C). We also testedwhether
the interaction between CDC20 and the APC is essential for GSC
invasiveness by using a pharmacological inhibitor of the APC,
ProTAME, which interferes with the binding of the CDC20 isoleu-
cine-arginine (IR) tail with the APC (Figures 1K and S2F; Zeng
et al., 2010). We confirmed exposure to ProTAME disrupts the
interaction between CDC20 and APC subunit CDC27 in GSCs
(Figure S2F). ProTAME treatment inhibited invasiveness in three
human GSC lines, suggesting CDC20 acts with the APC to con-
trol GSC invasion (Figures 1K, S2G, and S2H).
Next, we examined the role of CDC20 in GSC self-renewal, a
property that often parallels tumorigenic potential (Suva` et al.,
2014). We performed the extreme limiting dilution assay to mea-
sure the frequency of self-renewing cells and found that CDC20
knockdown decreased the percentage of self-renewing GSCs
by 45% (Figure 1L; Singh et al., 2004). In complementary exper-
iments, CDC20 overexpression increased the frequency of self-
renewing cells by 56% and 89% in two GSC lines, respectively
(Figures 1M and 1N). Exposure to APC inhibitor ProTAME also
inhibited GSC self-renewal (Figure 1O). Together, these experi-
ments indicate CDC20 operates with the APC to promote GSC
invasion and self-renewal.
Next, we asked whether cell-cycle perturbations triggered
by CDC20-APC manipulations might be responsible for the
observed effects on GSC invasion and self-renewal. Examina-
tion of cell-cycle profile revealed little to no change in the distri-
bution of cell-cycle phases in CDC20 knockdown GSCs
compared to that of control infected cells (Figure S3A). Addition-
ally, the degree of CDC20 knockdown achieved in these exper-
iments did not significantly alter cellular proliferation by the MTS
assay, although ANAPC2 knockdown modestly decreased
proliferation (Figure S3B). These data are consistent with thejected to live fluorescence microscopy. Scale bar, 10 mm.
ses (Vec) were assessed for invasion 5 days later. Data represent mean + SEM.
test, p = 0.01; n = 5).
led (Scr) lentivirus; 7 days later, cell lysates were subjected to immunoblotting
002 (data not shown).
days later. Data represent mean + SEM. ANAPC2 knockdown inhibited GSC
e of ProTAME or DMSO (Veh). Data represent mean + SEM. ProTAME inhibited
eme limiting dilution assay; 7 days later, the number of wells with spheres was
the percentage of self-renewing GSCs compared to control (unpaired t test,
s in (L). Data represent mean + SEM. CDC20 overexpression increased the
005, n = 3).
. Data representmean+SEM. CDC20 overexpression increased the percentage
n = 3).
E or DMSO (Veh) and analyzed as in (L). Data represent mean + SEM. ProTAME
t test, p < 0.0001; n = 3).
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Figure 2. CDC20-APC Interacts with SOX2 through the WD40 Repeat Domain of CDC20
(A) (Top) B18 GSCs transduced with lentiviruses expressing the indicated GFP-tagged mutant CDC20 proteins were subjected to live fluorescence microscopy.
Scale bar, 25 mm. (Bottom) GSCs treated as above were assessed for invasion 6 days later. Data represent mean + SEM. Expression of nuclear localized CDC20
(NLS-CDC20), but not cytoplasmic CDC20 (NES-CDC20), increased GSC invasiveness compared to control (ANOVA, p = 0.005; n = 5).
(B) Lysates of 293 cells transfected with GFP-CDC20 together with the myc-SOX2 expression plasmid or control vector were immunoprecipitated using myc
antibody and immunoblotted with the indicated antibodies.
(legend continued on next page)
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previously reported observation that CDC20 knockdown does
not significantly alter mitotic transition until CDC20 levels drop
below a critical threshold (Wolthuis et al., 2008). In other exper-
iments, CDC20 overexpression had little to no effect on the
cell-cycle distribution or proliferation of GSCs (Figures S3C–
S3F). These results support the hypothesis that CDC20 control
of GSC invasiveness and self-renewal can be separated from
CDC20 regulation of the cell cycle.
Next, we studied whether CDC20-APC control of GSC func-
tion might be a consequence of decreased cellular survival.
Importantly, we found that the degree of CDC20 and ANAPC2
knockdown achieved did not significantly alter cell survival in
GSCs (Figure S3G). Additionally, CDC20 RNAi did not signifi-
cantly increase caspase-3 activity in GSCs, and ANAPC2 RNAi
caused a mild increase in caspase-3 activity in only one of two
GSC lines (Figures S3H and S3I). In other experiments, short-
term treatment with APC inhibitor ProTAME revealed minimal
to no cell death in two GSC lines (Figure S3J; data not shown).
These results suggest alterations in cell survival were not signif-
icantly contributing to the invasion and self-renewal phenotypes
observed with CDC20-APC manipulations.
To understand the mechanism of CDC20-APC in GSC inva-
siveness, we turned to the question of where in the cell CDC20
operates to mediate invasiveness. Previous reports demon-
strated that specific subcellular pools of CDC20 dictate distinct
biological responses in neural development (Kim et al., 2009;
Puram et al., 2011). CDC20 localizes to both cytoplasmic and
nuclear compartments in GSCs (Figure 1G; Kallio et al., 1998).
To localize CDC20 to distinct subcellular locations, we gener-
ated viruses that expressmutant CDC20 fusion proteins carrying
either a nuclear localization sequence (GFP-NLS-CDC20) or nu-
clear export sequence (GFP-NES-CDC20), the latter localizing
CDC20 to the cytoplasm (Figure 2A). Expression of nuclear
CDC20 enhanced GSC invasiveness, whereas expression of
cytoplasmic CDC20 did not significantly alter invasive capacity,
suggesting CDC20-APC stimulates a nuclear program to drive
invasion (Figure 2A).
To elucidate the signal transduction pathway downstream of
CDC20-APC, we considered nuclear proteins implicated in
GSC invasiveness and self-renewal. The stem cell regulatory
gene SOX2 has received recent attention in the glioblastoma
field due to its critical roles in glioblastoma self-renewal, inva-
sion, and tumor propagation (Alonso et al., 2011; Gangemi
et al., 2009). We first tested whether a physical interaction exists
between CDC20 and SOX2. Remarkably, epitope-tagged
CDC20 and SOX2 were found in a complex in transfected 293(C) GSC line B18 lysates were immunoprecipitated with the CDC20 or control Ig
(D) GSC line B36 lysates were immunoprecipitated with the SOX2 or control IgG
(E) In-vitro-translated 35S-methionine-labeled CDC20mutant proteins were used i
Input (middle) confirms comparable levels of CDC20 mutants. CDC20 proteins w
used for pull-downs (Coomassie brilliant blue staining [CBB], right).
(F) Schematic depicts CDC20 domain structure (top) and summary of in vitro bin
(G) In-vitro-translated 35S-methionine-labeled SOX2 mutant proteins were used in
(aa 168–477, referred to asGST-CDC20) andGST proteins. SOX2 proteins were vi
representative experiment. Inputs confirm SOX2 mutants were produced at com
downs (CBB, far right). Images were background corrected.
(H) Schematic depicts SOX2 domain structure (top) and summary of in vitro bind
Cecells (Figure 2B). Moreover, we found CDC20 endogenously in-
teracts with SOX2 in two distinct GSC lines (Figures 2C and
2D). APC subunit CDC27 also was found in an endogenous
complex with SOX2, suggesting CDC20-APC interacts with
SOX2 (Figure 2C; data not shown). To determine whether
CDC20 binds directly to SOX2, we performedGST pull-down as-
says using recombinant GST-SOX2 fusion proteins and in vitro
translated CDC20, which revealed a robust direct interaction
(Figure 2E). Deletion mapping indicated the WD40 repeat
domain of CDC20 interacts directly with SOX2 in vitro (Figures
2E and 2F). Reciprocal GST pull-down assays using GST-fusion
proteins carrying the WD40 repeat domain of CDC20 (GST-
CDC20(WD40)) and in vitro translated deletion mutants of
SOX2 revealed CDC20(WD40) binds to SOX2 aa 1–200 and aa
124–317, suggesting SOX2 aa 124–200 are required for
CDC20 binding (Figures 2G and 2H). Indeed, the SOX2 deletion
mutant lacking aa 110–200 failed to bind CDC20(WD40) (Figures
2G and 2H). These data indicate CDC20-APC endogenously
interacts with SOX2 in GSCs likely via direct binding between
SOX2 aa 124–200 and the WD40 repeat domain of CDC20, sug-
gesting a mechanistic link between CDC20-APC and SOX2.
Differentiation of human GSCs in culture led to a dramatic
decrease in CDC20 protein levels, suggesting that, as with
SOX2, CDC20 is enriched in the GSC state (Figure 3A). To test
whether CDC20-APC regulates SOX2 in GSCs, we subjected
GSCs to CDC20 knockdown (Figures 3B and S4A). Intriguingly,
CDC20 RNAi decreased SOX2 protein levels in GSCs, and
co-expression of RNAi-resistant CDC20-Res with CDC20 RNAi
reversed this decrease, suggesting CDC20 specifically pro-
motes SOX2 protein expression (Figures 3B, 3C, and S4A).
Conversely, CDC20 overexpression in two GSC lines increased
SOX2 protein (Figures 3D and S4B). In other experiments, both
ANAPC2 knockdown and APC inhibitor ProTAME decreased
SOX2 protein in two GSC lines, suggesting collectively that
CDC20 collaborates with the APC to maintain SOX2 levels (Fig-
ures 3E–3G and S4C).
Next, we turned to the question of how CDC20-APC regulates
SOX2 protein levels, and we examined the effect of APC inhibitor
ProTAME on SOX2 protein over time in GSCs (Figure 3G; data
not shown). SOX2 protein levels began to decrease about 4 hr
after ProTAME exposure (Figure 3G; data not shown), but
SOX2 mRNA demonstrated little to no change after ProTAME
treatment over a similar time frame (Figures S4D and S4E). We
therefore examined the possibility that CDC20-APC controls
SOX2 protein stability. Consistent with this hypothesis, treat-
ment with proteasome inhibitor MG132 reversed the decreaseG antibody and immunoblotted with the indicated antibodies.
antibody and immunoblotted with the indicated antibodies.
n GST pull-down assays using recombinant GST-SOX2 and GST proteins (left).
ere visualized by fluorography. Similar amounts of GST and GST-SOX2 were
ding experiments (bottom).
GST pull-down assays using recombinant GST-CDC20 WD40 repeat domain
sualized by fluorography. A low exposure (left) and a high exposure (middle) of a
parable levels. Similar amounts of GST and GST-CDC20 were used for pull-
ing experiments (bottom).
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in SOX2 protein triggered by both ProTAME and CDC20 RNAi in
two GSC lines (Figures 3H, 3I, and S4F). Similar results were
seen using a different proteasome inhibitor, bortezomib, in the
setting of ProTAME, suggesting CDC20-APC stabilizes SOX2
protein (data not shown).
To determine the biochemical consequences of CDC20-APC
control of SOX2, we established a SOX2 transcriptional activity
reporter using a lentiviral GFP T2A luciferase expression vector
driven by the SOX2-responsive human SOX2 regulatory region
2 enhancer (hSRR2) (Figure 3J; Sikorska et al., 2008). We
confirmed GSCs infected with this SOX2 reporter virus exhibited
a hSRR2-specific GFP and luciferase signal compared to con-
trol reporter-infected cells; COS-1 cells, which do not express
SOX2, did not exhibit a hSRR2-dependent signal (Figure S4G).
CDC20 knockdown in GSCs substantially decreased the
hSRR2-driven luciferase signal compared to control RNAi, sug-
gesting CDC20 promotes SOX2-mediated transcription (Fig-
ure 3J). Accordingly, CDC20 knockdown and APC inhibitor
ProTAME decreased the mRNA levels of SOX2 target gene Nes-
tin (NES) in GSCs (Figures 3K and S4H; Berezovsky et al., 2014).
Together, these data indicate CDC20-APC positively regulates
SOX2 transcriptional activity in GSCs.
To determine the biological consequences of CDC20 regula-
tion of SOX2, we performed epistasis experiments using theFigure 3. CDC20-APC Regulation of SOX2 Protein and Transcription C
(A) GSCs (B18 and A1) were maintained in GSC or differentiating medium (Diff) (co
immunoblotting using the indicated antibodies.
(B) B18 GSCs were transduced with CDC20 RNAi (CDC20i.1 and CDC20i.2) or
immunoblotting using the indicated antibodies.
(C) GSCs were transduced with the indicated lentiviruses; 7 days later, cell lysates
of CDC20-Res rescued the CDC20 RNAi-triggered decrease in SOX2 protein. C
(D) GSCs transduced with CDC20-expressing lentivirus or control vector virus (Ve
immunoblotting using the indicated antibodies.
(E) GSCs were transduced with ANAPC2 RNAi or control LacZ RNAi (C) lentivirus;
antibodies.
(F) GSCs were treated with ProTAME or DMSO (Veh) for 12 hr. Cell lysates were
(G) GSCs were treated with 20 mM ProTAME or DMSO (Veh) as indicated. Cell ly
(H) GSCs were treated with 20 mMProTAME, 5 mMproteasome inhibitor MG132, o
using the indicated antibodies. Veh, DMSO.
(I) GSCs were transduced with CDC20 RNAi (CDC20i.2) or control SHC002 (C) le
lysates were subjected to immunoblotting using the indicated antibodies.
(J) GSCs stably infected with the SOX2 transcriptional reporter (hSRR2) or contr
scrambled (Scr) lentivirus; 7 days later, luciferase assays were performed. Lucifer
scaling to Scr +mCMV values ( = 1). Data represent mean + SEM.CDC20RNAi de
(K) GSCswere infected withCDC20RNAi (CDC20i.1 and CDC20i.2) or control scra
into cDNA. qPCR was performed on samples using specific primers for huma
mean + SEM. CDC20 RNAi decreased NES mRNA in GSCs compared to contro
(L) GSCs infected with the CDC20-expressing or control vector (Vec) lentivirus t
subjected to the in vitroMatrigel transwell assay 7 days later. Data represent mean
(ANOVA, p = 0.007; n = 6). Expression of CDC20 plus SOX2 RNAi reduced invasi
vector virus (ANOVA, p < 0.0001 and p = 0.001, respectively).
(M) GSCs infected with SOX2-expressing or control vector (Vec) lentivirus togeth
represent mean + SEM. CDC20 knockdown decreased invasiveness compared
increased invasion compared to infection with Vec plus CDC20 RNAi viruses (AN
(N) GSCs infected as in (L) were subjected to the extreme limiting dilution assay
increased self-renewal compared to control (ANOVA, p = 0.004; n = 3). Expressio
Scr plus either the CDC20-expressing or control virus (ANOVA, p < 0.0001 and p
(O) GSCs were transduced with the indicated lentiviruses and subjected to the in v
plus control vector virus (Vec) decreased GSC invasiveness compared to control
SOX2 RNAi-triggered defect in invasiveness (ANOVA, p < 0.0001), whereas SOX
See also Figure S4.
CeMatrigel invasion assay. We first confirmed that SOX2 knock-
down decreases GSC invasiveness in three GSC lines (Figures
3L, S4I, and S4J; Alonso et al., 2011). SOX2 RNAi did not signif-
icantly affect cellular survival or health by the propidium iodide
exclusion, MTS, and caspase-3 activity assays, consistent with
a prior report (Figures S4L and S4M; data not shown; Gangemi
et al., 2009). Whereas CDC20 overexpression increased GSC
invasiveness, the combination of CDC20 overexpression and
SOX2 RNAi decreased invasiveness to a level similar to that
of SOX2 RNAi alone (Figure 3L). In a second GSC line, SOX2
RNAi also inhibited the ability of CDC20 overexpression to
enhance invasiveness (Figure S4K). Conversely, SOX2 overex-
pression partially but significantly reversed the CDC20 RNAi-
induced invasion phenotype (Figure 3M), together suggesting
that SOX2 acts downstream of CDC20 to drive invasiveness.
The increase in GSC self-renewal triggered by CDC20 overex-
pression also was inhibited by SOX2 knockdown in two GSC
lines (Figure 3N; data not shown), indicating SOX2 functions
downstream of CDC20 to control self-renewal. To test whether
the binding of CDC20 to SOX2 is critical for GSC invasion, struc-
ture-function experiments were performed in the setting of SOX2
RNAi (Figures 3O and S4N). Using a SOX2 cDNA carrying seven
base mismatches in the sequence targeted by SOX2 RNAi
(SOX2-Res), we generated lentiviruses that express full-lengthontrols GSC Invasion and Self-Renewal
ntaining FBS and no growth factors) for 14 days. Cell lysates were subjected to
control LacZ RNAi (C) lentivirus; 7 days later, cell lysates were subjected to
were subjected to immunoblotting using the indicated antibodies. Expression
, SHC002 virus; Vec, control vector virus.
c) were maintained in RHB-A media for 5 days. Cell lysates were subjected to
7 days later, cell lysates were subjected to immunoblotting using the indicated
subjected to immunoblotting using the indicated antibodies.
sates were subjected to immunoblotting using the indicated antibodies.
r a combination of both for 8 hr. Cell lysates were subjected to immunoblotting
ntivirus for 7 days and treated with 10 mM MG132 or DMSO (Veh) for 6 hr. Cell
ol reporter (mCMV) were transduced with CDC20 RNAi (CDC20i.2) or control
ase values were normalized by total protein and fold change was calculated by
creased SOX2 reporter activity compared to control (ANOVA, p < 0.0001, n = 3).
mbled (Scr) lentivirus. RNAwas harvested 7 days later and reverse transcribed
n NES. GAPDH and ACTB were used as reference genes. Data represent
l (ANOVA, p < 0.0001; n = 3).
ogether with the SOX2 RNAi (SOX2i) or control SHC002 RNAi (Scr) virus were
+ SEM. Expression of CDC20 increased invasion compared to control infection
on compared to infection with Scr plus either the CDC20-expressing or control
er with CDC20 RNAi or control SHC002 RNAi (Scr) were treated as in (L). Data
to control (ANOVA, p < 0.0001; n = 4). Expression of SOX2 plus CDC20 RNAi
OVA, p = 0.011).
as in Figure 1L. Data represent mean + SEM. Expression of CDC20 plus Scr
n of CDC20 plus SOX2 RNAi reduced self-renewal compared to infection with
= 0.001, respectively).
itro Matrigel transwell assay as in (L). Data represent mean + SEM. SOX2 RNAi
(ANOVA, p < 0.001; n = 6). Expression of full-length SOX2-Res (FL) rescued the
2-ResD110–200 did not (ANOVA, p = 0.9).
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SOX2-Res and mutant SOX2-ResD110–200, the latter of which
does not bind CDC20 in vitro (Figures 2G and 2H). Whereas
expression of full-length SOX2-Res rescued theSOX2RNAi-trig-
gered deficit in invasion, SOX2-ResD110–200 did not, suggest-
ing the binding of SOX2 to CDC20 is important for GSC invasion
(Figure 3O).
To examine the relevance of CDC20-APC in GSC tumorige-
nicity in vivo, we used two GSC lines stably expressing GFP
T2A luciferase, enabling GFP immunofluorescence as well as
bioluminescence imaging (BLI) in live animals to monitor tumor
burden (Figures 4A and 4B). GSCs infected with CDC20 RNAi
or control virus were injected into the brains of NOD-SCIDg
mice. BLI performed over several months revealed CDC20
knockdown inhibited brain tumor formation (Figures 4A and
4B). GFP immunofluorescence in brain sections of injected
mice demonstrated infiltrative tumors corresponding to the BLI
signal (Figure 4B; data not shown). In other experiments, we
infected a third GSC line with CDC20 RNAi or control virus,
injected these cells into the brains of NOD-SCID mice, and
sacrificedmice 3months later to assess tumorigenicity by immu-
nofluorescence (Figures 4C and S5). Control-infected GSCs
formed brain tumors in all eight animals, while CDC20 RNAi-in-
fected GSCs formed tumors in only two of six animals, suggest-
ing again that CDC20 is critical for the tumor-initiating potential
of GSCs (Figure 4C). In complementary experiments, GSCs sta-
bly expressing luciferase were infected with CDC20-expressing
or control virus, injected into NOD-SCIDgmice, and assessed for
brain tumor growth by BLI, which showed that CDC20 overex-
pression enhances tumor growth in vivo (Figure 4D). Together,
these experiments indicate CDC20 drives the in vivo tumorige-
nicity of human GSCs.
We interrogated the Cancer Genome Atlas (TCGA) to investi-
gate whether CDC20 expression correlates with clinical out-
comes in glioblastoma patients. Consistent with prior reports,
we foundCDC20mRNA is significantly elevated in glioblastomas
compared to normal brain (Figure 5A; Bie et al., 2011; Marucci
et al., 2008). We then assessed CDC20 expression in the four
TCGA-based molecular subtypes—Proneural, Mesenchymal,
Classical, andNeural—and found the Proneural subtype demon-
strated significantly higher CDC20 expression compared to the
other subtypes (Figure 5B; Verhaak et al., 2010). We stratified
the glioblastoma patients with valid survival data into high
(2-fold change or greater compared to normal brain) and low
CDC20mRNA groups, and we observed thatCDC20 expression
in the entire population was not significantly associated with
overall survival (OS) (Figure 4C). We then performed Kaplan-
Meier survival analyses on patients with high or low CDC20
mRNA expression within each subtype (Figure 4D). Although
CDC20 expression did not correlate with OS within the Mesen-
chymal, Classical, or Neural subtypes, patients with high
CDC20-expressing Proneural tumors exhibited a substantially
shorter OS (median 53.9 weeks) compared to that of patients
with low CDC20-expressing tumors (median 219.6 weeks) (Fig-
ure 4D). We confirmed this association using a Cox proportional
hazard model to identify an optimal cutoff for CDC20 expression
in relation to OS, which also indicated a significant correlation
between high CDC20 expression and shorter OS specifically in
the Proneural subtype (Figures S6A and S6B).1816 Cell Reports 11, 1809–1821, June 23, 2015 ª2015 The AuthorsSomatic mutations in the isocitrate dehydrogenase 1 gene
(IDH1) are found in a subset of Proneural patients with longer
OS than patients with IDH1 wild-type (WT) tumors (Hartmann
et al., 2010; Parsons et al., 2008; Yan et al., 2009). We asked
whether CDC20 expression might interact with IDH1 mutation
status or represent an independent prognostic marker in Pro-
neural glioblastomas (Figures S6C and S6D). When IDH1 MUT
tumors were included, Proneural tumor patients with high
CDC20 expression again had a poorer prognosis (Figure S6C).
When IDH1 MUT tumors were excluded, the number of Proneral
tumor patients with low CDC20 expression was small (six pa-
tients with four censored), but the OS of patients with high and
low CDC20 tumors was not appreciably different, suggesting
an interaction between IDH1 mutation and CDC20 expression
(Figure S6C). We then examined gene expression data for Pro-
neural tumors only, and we found IDH1 MUT tumors exhibit
significantly lower CDC20 expression compared to that of
IDH1 WT tumors (Figure S6D). Together, these data indicate
CDC20 expression is prognostic of OS in Proneural glioblas-
tomas and, in a limited subset analysis, appears to interact
with IDH1 mutation status.
DISCUSSION
In this study, we have demonstrated CDC20-APC operates
through SOX2 to control human GSC invasion and self-renewal.
Additionally, we have found CDC20 is critical for human GSC
tumorigenicity in vivo. Interrogation of the TCGA revealed high
CDC20 expression was associated with decreased OS in Pro-
neural subtype glioblastomas.
CDC20-APC has been studied intensively in the cell-cycle field
and is viewed as a promising target in several human cancers
(Wang et al., 2015). As proof of concept, conditional Cdc20
knockout in mouse models of skin cancer and fibrosarcoma
caused mitotic arrest and apoptotic tumor regression (Man-
chado et al., 2010). Intriguingly, the essential role of CDC20 in
GSC invasiveness and self-renewal appears to be separable
from CDC20’s known role in cell-cycle regulation; the CDC20
manipulations used herein did not obviously affect proliferation
or cell-cycle parameters, consistent with the previous finding
that only aminimal level of CDC20 is needed formitotic transition
(Wolthuis et al., 2008). More recently, CDC20 knockdown was
shown to sensitize cancer cells to chemotherapy and radiation
therapy (Wan et al., 2014). Our results reinforce the rationale
for the development of CDC20-APC inhibitors in glioblastoma,
not only to reduce tumor burden through cell-cycle and cell-
death mechanisms but also to disrupt key functional properties
of GSCs.
As with SOX2, CDC20 protein is enriched in human GSCs
compared to glioblastoma cells differentiated in vitro. This
finding, which remains to be validated in human tumor samples
ex vivo, raises interesting questions about how CDC20 is regu-
lated in the GSC state. Downstream of CDC20, regulation of
SOX2 appears to occur at two—not necessarily mutually exclu-
sive—levels: CDC20 binding to SOX2 and CDC20-APC control
of SOX2 protein stability. SOX2 binding to CDC20 appears to
be important for SOX2 control of GSC invasiveness (Figures
2H and 3O). It is possible that CDC20 binding enhances SOX2
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Figure 4. CDC20 Drives GSC Tumorigenicity In Vivo
(A) B36 GSCs stably infected with CMV-driven GFP T2A luciferase lentivirus were transduced with CDC20 RNAi or control LacZ RNAi (LacZi) lentivirus and
injected into the right putamen of NOD-SCIDg mice. Injected mice were subjected to live BLI. (Top) Data represent mean ± SEM (n = 5 animals per condition).
CDC20 knockdown decreased GSC tumorigenicity compared to control (unpaired t test, *p < 0.01, #p < 0.05). (Bottom) Representative animals subjected to BLI
are shown.
(B) B49 GSCs stably infected with CMV-driven GFP T2A luciferase lentivirus were treated as in (A) and injected into the brains of NOD-SCIDgmice. Injected mice
were subjected to live BLI. (Top) Data represent mean ± SEM (n = 5 animals per condition). CDC20 knockdown decreased GSC tumorigenicity compared to
control (unpaired t test, *p < 0.05). (Bottom) Injected mice were sacrificed at 5 months. Representative coronal brain sections subjected to GFP immunofluo-
rescence to visualize tumor are shown. Nuclei were stained with DAPI. Scale bar, 100 mM.
(C) B18 GSCs infected with CDC20i.2 or control SHC002 (Scr) virus were injected into the brains of NOD-SCID as in (A); 3 months after injection, animals were
sacrificed and brains were processed for immunohistochemistry using antibodies against NES and GFAP. Nuclei were stained with Hoechst 33342. The number
of animals harboring a brain tumor in each treatment group is indicated. CDC20 knockdown decreased GSC tumorigencity compared to control (Fisher’s exact
test, p = 0.015).
(D) B36 GSCs stably infected with CMV-driven GFP T2A luciferase lentivirus were transduced with GFP-CDC20-expressing or control vector lentivirus and
injected into the brains of NOD-SCIDgmice as in (A). Injectedmice were subjected to live BLI. (Left) Data presented aremean ±SEM (n = 4 animals per condition).
CDC20 overexpression increased tumor formation compared to control (unpaired t test, p < 0.04). (Right) Representative animals subjected to BLI are shown.
See also Figure S5.
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Figure 5. High CDC20 Expression Is Associated with Decreased OS in Proneural Subtype Glioblastomas
(A) Box plot (median and middle 50% of data represented in each box) for CDC20 mRNA expression in TCGA glioblastoma (n = 473) and normal brain tissue
samples (n = 10). CDC20 expression is higher in glioblastoma samples compared to normal tissue (unpaired t test, p = 9.62 3 1014).
(B) Box plot for normalized CDC20 gene expression (compared to normal samples) demonstrates the highest level of CDC20 expression in the Proneural subtype
compared to other subtypes (Holm’s adjustment for multiplicity, p < 0.0001).
(C) Kaplan-Meier curves showingOSof 466 newly diagnosed glioblastomapatients from the TCGAbased onCDC20 expression. HighCDC20 represents 2-fold or
greater expression and lowCDC20 represents less than2-fold expression compared tomeanCDC20expression in normal brain samples (log-rank test, p =0.390).
(D) Kaplan-Meier curves showing OS of TCGA patients separated by molecular subtype based on CDC20 expression. Data were analyzed as in (C). High CDC20
expression was associated with decreased OS only in patients with Proneural tumors (log-rank test, p = 0.002).
See also Figure S6.
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function, perhaps through the CDC20-APC-dependent recruit-
ment of transcriptional activators (Turnell et al., 2005). The exact
mechanistic link between CDC20-APC and SOX2 protein stabil-
ity remains an important open question. SOX2 regulation by the
ubiquitin-proteasome system has only recently begun to be
examined in the context of non-cancerous cells, such as embry-
onic stem cells (ESCs). Whereas SOX2 acetylation and methyl-
ation increase SOX2 degradation, phosphorylation of murine
SOX2 at Thr118 (Thr116 in human SOX2) by AKT stabilizes
SOX2 protein, raising the possibility that CDC20-APC might
affect SOX2 stability by altering SOX2 post-translational modifi-
cations (Baltus et al., 2009; Fang et al., 2014; Jeong et al., 2010).
Alternatively, CDC20-APCmay act indirectly on SOX2 by ubiqui-
tinating and destroying a critical E3 ligase, which targets SOX2.
Only two E3 ligases that target and degrade SOX2 have been
reported so far. One is FZR1 (also CDH1), an alternative co-acti-
vator of the APC, which is responsible for G1 maintenance (Fu-
kushima et al., 2013). However, we found little to no change in
SOX2 protein levels in the setting of CDH1 RNAi in GSCs, and
ANAPC2 RNAi and APC inhibitor ProTAME, which inhibit both
CDH1-APC and CDC20-APC, decreased SOX2 protein, sug-
gesting a dominant role for CDC20-APC in SOX2 protein regula-
tion in GSCs (Figures 3E–3G; data not shown). More recently,
WWP2 was identified as a SOX2 ubiquitin ligase in ESCs (Fang
et al., 2014). Whether WWP2 or other E3 ligases contribute to
SOX2 stability in glioblastoma remain to be determined.
Our results have several intriguing implications for CDC20-
APC’s role in the transcriptional networks governing glio-
blastoma molecular subtypes as well as non-cancerous stem/
progenitor cells. Interestingly, we have found in the TCGA
dataset that CDC20 expression is particularly elevated in the
Proneural subtype. Since SOX2 is a known Proneural signature
gene, the finding that CDC20-APC promotes SOX2-dependent
transcription raises the intriguing hypothesis that CDC20-APC
stimulates Proneural signature gene transcription (Verhaak
et al., 2010). The CDC20-APC/SOX2 mechanism therefore
might be particularly relevant for the biology underlying this
molecular subtype. As a prognostic marker, CDC20 expression
appears to interact with IDH1 mutation, suggesting a potential
mechanistic link between IDH1 mutant status and low CDC20
expression. But the exact relationship between CDC20 expres-
sion and survival in the bulk tumor data of the TCGA and the
CDC20-APC/SOX2 mechanism in GSCs require further investi-
gation. For instance, in contrast to bulk tumor, human GSCs
cluster into predominantly two molecular subtypes—Proneural
and Mesenchymal (Bhat et al., 2013). The molecular subtyping
of the human GSC lines utilized in this study suggests the con-
trol of core GSC functions by the CDC20-APC/SOX2 signaling
axis is generalizable and independent of GSC subtype (Fig-
ure S1A). Additionally, current mRNA and genome-based bulk
tumor datasets may not reflect the SOX2 protein regulatory
mechanisms reported herein, which will require interrogation
of proteomic datasets. More speculatively, the CDC20-APC/
SOX2 pathway may play a role in the transcriptional program
in other cellular contexts, including the regulation of neural
stem cells and, potentially, the maintenance of pluripotency in
embryonic or induced pluripotent stem cells (Lewitzky and Ya-
manaka, 2007; Pevny and Nicolis, 2010).CeAlthough the mechanisms of SOX2’s critical role in self-
renewal have been investigated extensively in the context of
stem cell biology and cancer (He et al., 2009), the downstream
mechanisms that specifically drive SOX2-dependent invasion
in glioblastoma remain to be identified. SOX2 has been impli-
cated in promoting the invasive potential of other cancers,
raising the possibility that CDC20-APC control of SOX2 might
regulate invasion in diverse cancers (Forghanifard et al., 2014;
Girouard et al., 2012; Han et al., 2012; Lou et al., 2013; Xia
et al., 2014). Future analyses of SOX2 transcriptional targets
will be important to elucidate the precise mechanisms of
SOX2-mediated invasiveness specifically in glioblastoma.
Moreover, given the multitude of identified CDC20-APC sub-
strates, it is likely that additional, SOX2-independent mecha-
nisms contribute to CDC20-APC regulation of GSC invasiveness
and self-renewal.
EXPERIMENTAL PROCEDURES
Cell Culture
The generation of adherent human GSC cultures has been described
previously (Pollard et al., 2009). In brief, tumor samples obtained directly
from surgery were dissociated by mincing and incubation in Accutase
(Sigma-Aldrich) for 20–60 min at 37C. Cell suspensions were passed
through a 70-mm cell strainer (Falcon) and plated using Ndiff RHB-A media
(Stem Cell Sciences) with EGF and FGF-2 (PeproTech) (hereafter called
GSC media) each at 20 ng/ml, on polyornithine- and laminin- (Sigma-
Aldrich) coated Primaria dishes/flasks (BD Biosciences). Media were re-
placed with half fresh GSC media every 2–3 days. Cells were routinely
used between passages 5 and 20. Informed consent was obtained from pa-
tients for use of human tissue and cells, and all human tissue-related pro-
tocols used in this study were approved by the Institutional Review Board
(Washington University). Primary human astrocytes (Lonza) were cultured
in astrocyte growth media (Lonza). HEK293 cells were cultured in DMEM
with 10% fetal bovine serum (FBS) and penicillin/streptomycin (Life Tech-
nologies). All cell lines were incubated at 37C with 5% CO2. Lentiviral
transduction was performed by adding virus with 4 mg/ml polybrene for
4 hr to cells. For rescue or epistasis experiments, GSCs were transduced
with RNAi or control lentivirus 1 day after plating, and then transduced
with CDC20-Res expression virus or control virus the following day. Cells
were selected in 2 mg/ml puromycin 1–2 days after infection. For self-
renewal and in vivo tumorigenicity experiments, GSCs were utilized
4 days following indicated viral infections.
Cell Invasion Assay
The in vitro cell invasion assay was performed using Matrigel-coated invasion
chambers (BD Biosciences) (Valster et al., 2005). In 24-well plates, 5 3 104
GSCs in GSC media was added to the upper chamber of a rehydrated, Matri-
gel-coated polycarbonate membrane filter. The bottom chamber of the well
was pre-filled with RHB-A media containing 10% FBS as chemoattractant.
After 24 hr, non-invasive cells from the upper side of the filter were removed
using a moist cotton swab. The invasive cells on the reverse side of the filter
were then fixed and stained with DAPI nuclear dye, and images of the cells
were captured in a blinded fashion in three different low-power fields (53
objective) per condition using a fluorescence microscope (Leica Microsys-
tems, DMI4000 B). Quantitation of invasion also was performed in a blinded
fashion using ImageJ software (NIH).
Extreme Limiting Dilution Analysis
Cells were plated at 5-fold dilutions (3,000, 600, 120, 24, 5, or 1 cell/well)
in Corning ultra-low attachment 96-well plates. Then, 7–10 days later, the
number of wells containing spheres was counted and used to calculate the
frequency of self-renewing GSCs by online software (http://bioinf.wehi.edu.
au/software/elda/; Hu and Smyth, 2009; Singh et al., 2004).ll Reports 11, 1809–1821, June 23, 2015 ª2015 The Authors 1819
Xenotransplantation
Animals were used in accordance with a protocol approved by the Animal
Studies Committee of the Washington University School of Medicine per the
recommendations of the Guide for the Care and Use of Laboratory Animals
(NIH). Per animal, 250,000 cells (unless otherwise noted) were injected stereo-
tactically into the right putamen of approximately 6-week-old male NOD-
SCIDg mice (for B36 and B49) or female NOD-SCID mice (for B18) (Hope
Center Animal Surgery Core, Washington University). The coordinates used
were: 1 mm rostral to bregma, 2 mm lateral, and 2.5 mm deep.
Statistics
All images are representative of results from three independent experiments
unless otherwise stated. Statistical analyses were performed with XLSTAT
(Addinsoft), Excel (Microsoft), or R Version 3.1.1 software. The unpaired
Student’s t test was used for comparisons in experiments with only two
groups. In experiments with more than two comparison groups, ANOVA was
performed followed by Fisher’s least significant difference or the Bonferroni
test for pairwise comparisons among three and greater than three groups,
respectively.
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